I was born in Brooklyn, and although I lived elsewhere during college and residency training, I consider myself a lifelong New Yorker. While getting my MD and PhD in molecular pharmacology from Albert Einstein College of Medicine in the Bronx, I realized I was especially fascinated by the field of dermatology. I loved taking care of children when I rotated through pediatrics as a medical student, so I chose to combine these interests and specialize in pediatric and adolescent dermatology.
I arrived at NYU Langone in 1990, joining one of the leading dermatology departments in the world. Whether treating a newborn or a college student, I want to do everything I can to help my patients and to support their families, while always balancing the benefits and risks of a particular treatment.
In my research, I have worked to determine the risks associated with certain birthmarks and skin growths, such as hemangiomas, and have collaborated with molecular geneticists to identify genetic changes that cause congenital skin conditions. I’ve also worked to improve how we treat eczema and psoriasis in children and teenagers. In 2003, I received a Lifetime Achievement Award from the American Skin Association.
This provider accepts the following insurance plans.
Blue Cross Blue Shield
- BCBS EPO - Empire EPO (NYU Langone Employees)
- BCBS EPO - Empire EPO (Sunset Park/Family Health Center Employees)
- BCBS EPO - Empire NYU Care (NYU Langone Employees)
- BCBS EPO - Empire NYU Care (Sunset Park/Family Health Center Employees)
- BCBS PPO - Empire PPO (Sunset Park/Family Health Center Employees)
- World Trade Center - Logistic Health Incorporated
- United Healthcare EPO (NYU Langone Health Employees)
- United Healthcare Indemnity (NYU Langone Health Employees)
- United Healthcare Plus (NYU Langone Health Employees)
WTC Health Program
- WTC Health Program
“My research has improved treatments for eczema and psoriasis in children and teenagers.”Seth J. Orlow, MD, PhD Pediatric Dermatologist
development of novel targeted therapies in melanoma and other cancers, molecular and cellular basis of pigmentation, cancer, pharmacology
1. Development of novel therapeutics for the treatment of a number of cancers including melanoma and multiple myeloma, as well as unraveling pathways underlying chemoresistance in these tumors. To do so, we utilize small molecule screening of already-approved drugs ("drug repositioning") and of natural products combined with molecular and cellular techniques. 2. Understanding the cell biology of melanin synthesis and deposition in the skin, hair and eyes, including the processing and trafficking of tyrosinase, the rate-limiting enzyme in melanin production, as well as the pathogenesis of various forms of oculocutaneous albinism that diminish pigmentation. 3. Elucidating the pathogenesis of vitiligo, in which melanocytes in the skin are destroyed, including the role of endoplasmic reticulum stress and the unfolded protein response.
222 East 41st Street
New York, NY 10017
Journal of the American Academy of Dermatology. 2021 Oct ; 85(4):878-884
Pediatric dermatology. 2021 Sep ; 38(5):1127-1131
Journal of the American Academy of Dermatology. 2021 Jun ; 84(6):1594-1601